GTx, Inc. (GTXI) Posts Earnings Results
GTx, Inc. (NASDAQ:GTXI) announced its quarterly earnings results on Monday. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter.
Shares of GTx (NASDAQ:GTXI) traded down 4.44% during trading on Tuesday, reaching $4.30. 48,493 shares of the company were exchanged. The firm’s market capitalization is $68.98 million. GTx has a 1-year low of $4.01 and a 1-year high of $11.19. The firm’s 50 day moving average is $4.62 and its 200 day moving average is $4.30.
A number of brokerages recently issued reports on GTXI. ValuEngine cut shares of GTx from a “sell” rating to a “strong sell” rating in a research note on Thursday, May 11th. Zacks Investment Research cut shares of GTx from a “buy” rating to a “hold” rating in a research note on Tuesday, February 7th.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/16/gtx-inc-gtxi-posts-earnings-results.html.
A hedge fund recently raised its stake in GTx stock. Geode Capital Management LLC raised its position in GTx, Inc. (NASDAQ:GTXI) by 0.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,531 shares of the biopharmaceutical company’s stock after buying an additional 276 shares during the period. Geode Capital Management LLC owned about 0.25% of GTx worth $192,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 96.51% of the company’s stock.
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.